BOLT Bolt Biotherapeutics (BOLT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001641281
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about BOLT
Insiders, 180 days
-$123.8K net sold
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan
Bolt Biotherapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Bolt Biotherapeutics, Inc. insiders sold a net $123.8K of stock across 65 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 15 earlier Form 4 trades (code P or S) here by this insider (13 buys, 2 sales), the last on Sep 17, 2026.
- -14.6% median (-9.1% mean) 90-day return after 13 previous buys.
- The trade is 36.0% of the 25,384 shares held after it.
- 2 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO and CFO Quinn William P. sold about $29.6K of BOLT on Sep 18, 2026, the largest insider sale at the company since 2023; 2 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on Sep 17, 2026.
- +12.9% median (+13.0% mean) 90-day return after 3 previous buys.
- The trade is 39.7% of the 17,269 shares held after it.
- 2 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Yonehiro Grant sold about $22.2K of BOLT on Sep 18, 2026, the largest insider sale at the company since 2023; 2 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (5 buys, 2 sales), the last on Sep 17, 2026.
- -19.7% median (-18.5% mean) 90-day return after 5 previous buys.
- The trade is 23.9% of the 17,082 shares held after it.
- 2 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Senior VP, Finance and PAO Nemec Sarah sold about $13.2K of BOLT on Sep 18, 2026; 2 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (13 buys, 1 sale), the last on Sep 16, 2026.
- -14.6% median (-9.1% mean) 90-day return after 13 previous buys.
- The trade is 19.0% of the 34,516 shares held after it.
- 2 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO and CFO Quinn William P. sold about $21.7K of BOLT on Sep 17, 2026, the largest insider sale at the company since 2023; 2 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Sep 16, 2026.
- +12.9% median (+13.0% mean) 90-day return after 3 previous buys.
- The trade is 20.4% of the 24,119 shares held after it.
- 2 other insiders sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Yonehiro Grant sold about $16.3K of BOLT on Sep 17, 2026, the largest insider sale at the company since 2023; 2 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.65 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$123.8K over 180 days
-$128.3K over 90 days
more than 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
+0.1% year over year
below 53% of Pharma & Biotech
Margin
-433.7% net margin
below 76% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.6% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BOLT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+10.6%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BOLT: institutional holders (13F)
13F holdings, latest reported quarter
137,721 sh
$530.2K
98,625 sh
$379.7K
72,414 sh
$278.8K
61,600 sh
$237.2K
56,903 sh
$219.1K
Congress trades in BOLT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BOLT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BOLT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$89.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$27.2K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$28.1K position · as of 2026-05-31
0.0%
Diversified Equity Alpha Master Portfolio
$343 position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.9K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$751 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 2
0 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $123.8K sold by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BOLT financials
Revenue growth
+0.1%
XBRL, annual
Net margin
-433.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BOLT
| FY Dec 2025 | $7.7M |
| FY Dec 2024 | $7.7M |
| FY Dec 2023 | $7.9M |
| FY Dec 2022 | $5.7M |
| FY Dec 2021 | n/a |
| Jun 2026 | $5.0K |
| Mar 2026 | $26.0K |
| Dec 2025 | $2.5M |
| Sep 2025 | $2.2M |
| Jun 2025 | $1.8M |
| Mar 2025 | $1.2M |
| Dec 2024 | $0 |
| Sep 2024 | $1.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-611.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BOLT
| FY Dec 2025 | -433.7% |
| FY Dec 2024 | -820.8% |
| FY Dec 2023 | -878.6% |
| FY Dec 2022 | -1,538% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -265.2% |
| Sep 2025 | -329.4% |
| Jun 2025 | -474.6% |
| Mar 2025 | -903.4% |
| Dec 2024 | n/a |
| Sep 2024 | -1,330% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$61.3M |
| FY Dec 2023 | -$69.7M |
| FY Dec 2022 | -$78.5M |
| FY Dec 2021 | -$59.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$7.2M |
| Sep 2025 | -$9.8M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$14.4M |
| Sep 2024 | -$14.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-111.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BOLT
| FY Dec 2025 | -79.7% |
| FY Dec 2024 | -74.3% |
| FY Dec 2023 | -48.7% |
| FY Dec 2022 | -41.8% |
| FY Dec 2021 | -135.8% |
| Jun 2026 | -111.6% |
| Mar 2026 | -88.8% |
| Dec 2025 | -79.7% |
| Sep 2025 | -82.0% |
| Jun 2025 | -81.3% |
| Mar 2025 | -83.9% |
| Dec 2024 | -74.3% |
| Sep 2024 | -65.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-49.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BOLT
| FY Dec 2025 | -42.7% |
| FY Dec 2024 | -48.7% |
| FY Dec 2023 | -35.7% |
| FY Dec 2022 | -32.9% |
| FY Dec 2021 | -55.7% |
| Jun 2026 | -49.6% |
| Mar 2026 | -44.2% |
| Dec 2025 | -42.7% |
| Sep 2025 | -48.9% |
| Jun 2025 | -50.8% |
| Mar 2025 | -55.4% |
| Dec 2024 | -48.7% |
| Sep 2024 | -45.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-64.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BOLT
| FY Dec 2025 | -54.7% |
| FY Dec 2024 | -65.5% |
| FY Dec 2023 | -44.3% |
| FY Dec 2022 | -36.8% |
| FY Dec 2021 | -57.7% |
| Jun 2026 | -64.3% |
| Mar 2026 | -55.9% |
| Dec 2025 | -54.7% |
| Sep 2025 | -62.8% |
| Jun 2025 | -64.5% |
| Mar 2025 | -68.6% |
| Dec 2024 | -65.5% |
| Sep 2024 | -61.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | -15.0% |
| FY Dec 2023 | -8.2% |
| FY Dec 2022 | -8.0% |
| FY Dec 2021 | -1.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -23.2% |
| Mar 2025 | -18.9% |
| Dec 2024 | -15.0% |
| Sep 2024 | -12.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BOLT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M |
| EPS (diluted) | -17.85 | -33.06 | -1.83 | -2.36 |
| Operating cash flow | -$39.9M | -$61.3M | -$69.5M | -$76.5M |
| Cash | $11.7M | $7.2M | $10.8M | $9.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
BOLT Stock Sonar score 5/7 axes
Find similar shapesCompareBOLT ranks highest on risk and compliance (78th percentile) and insider conviction (66th), and lowest on institutional and government (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BOLT filings, in plain words
Are Bolt Biotherapeutics insiders buying or selling BOLT?
In the 180 days to 2026-10-28, Bolt Biotherapeutics insiders were net sellers, a net $123.8K: $4.4K of purchases and $128.3K of sales reported on Form 4, by 2 buyers and 3 sellers.
Read the full summary
In the 180 days to 2026-10-28, Bolt Biotherapeutics insiders were net sellers of BOLT, a net $123.8K across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. Sales outweighed purchases more than tenfold by value. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
